

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
July 19, 2018**

**ORDER GRANTING CONFIDENTIAL TREATMENT  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**Arcturus Therapeutics Ltd.**

**File No. 001-35932 - CF#36402**

---

Arcturus Therapeutics Ltd. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 20-F filed on May 14, 2018, as amended on July 10, 2018.

Based on representations by Arcturus Therapeutics Ltd. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 4.7	through May 14, 2021
Exhibit 4.8	through May 14, 2021
Exhibit 4.9	through May 14, 2021
Exhibit 4.10	through May 14, 2021
Exhibit 4.11	through May 14, 2021
Exhibit 4.12	through May 14, 2021
Exhibit 4.13	through May 14, 2021
Exhibit 4.14	through June 15, 2023
Exhibit 4.15	through May 14, 2021

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields  
Secretary